Thyrotoxicosis with pegylated interferon alfa-2b.

Area of Science:

• Oncology
• Immunology
• Endocrinology

Background:

• Stage III melanoma presents a high risk of relapse and mortality post-surgery.
• Adjuvant interferon alfa therapy is the sole established treatment to improve relapse-free survival in melanoma.
• Emerging evidence suggests a positive prognostic impact of interferon-induced autoimmune conditions.

Observation:

• A 27-year-old woman with stage IIIa melanoma received 5-year adjuvant pegylated interferon alfa-2b.
• The patient developed dose-dependent thyrotoxicosis, managed with propylthiouracil.
• Spontaneous resolution of hyperthyroidism occurred after 4 years, while interferon treatment continued.

Findings:

• Hyperthyroidism, though less common than hypothyroidism with interferon, can occur.
• This case demonstrates atypical spontaneous resolution of interferon-induced hyperthyroidism during ongoing therapy.
• The patient remained relapse-free 7 years post-diagnosis.

Implications:

• Interferon-associated autoimmunity may correlate with a better prognosis in melanoma patients.
• This case highlights the complex interplay between interferon therapy, autoimmunity, and clinical outcomes.
• Further research is warranted to understand the mechanisms and clinical significance of interferon-induced autoimmunity in melanoma treatment.